Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed...
2 KB (84 words) - 12:19, 13 May 2023
GDF (10 (BMP3B), 11 (BMP11)) TGFβ (1, 2, 3) Antibodies: Fresolimumab Lerdelimumab Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761...
67 KB (8,184 words) - 20:48, 31 October 2024
GDF (10 (BMP3B), 11 (BMP11)) TGFβ (1, 2, 3) Antibodies: Fresolimumab Lerdelimumab Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761...
48 KB (5,338 words) - 23:42, 9 November 2024
GDF (10 (BMP3B), 11 (BMP11)) TGFβ (1, 2, 3) Antibodies: Fresolimumab Lerdelimumab Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761...
13 KB (1,405 words) - 18:36, 28 October 2024
lepirudin (INN) leptacline (INN) Leqembi Leqselvi lercanidipine (INN) lerdelimumab (INN) lergotrile (INN) leridistim (INN) lerisetron (INN) leritine lersivirine...
8 KB (379 words) - 05:02, 25 September 2024
Gavilimomab CD154 Frexalimab Ruplizumab BLyS Belimumab CAT Bertilimumab Lerdelimumab Metelimumab Integrin Natalizumab Vedolizumab Interleukin-6 receptor Tocilizumab...
7 KB (299 words) - 13:45, 27 April 2024
GDF (10 (BMP3B), 11 (BMP11)) TGFβ (1, 2, 3) Antibodies: Fresolimumab Lerdelimumab Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761...
41 KB (4,835 words) - 00:58, 10 October 2024
chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia Lerdelimumab mab human TGF-β2 reduction of scarring after glaucoma surgery Leronlimab...
137 KB (4,083 words) - 21:25, 19 October 2024
GDF (10 (BMP3B), 11 (BMP11)) TGFβ (1, 2, 3) Antibodies: Fresolimumab Lerdelimumab Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761...
6 KB (596 words) - 05:15, 1 January 2024
GDF (10 (BMP3B), 11 (BMP11)) TGFβ (1, 2, 3) Antibodies: Fresolimumab Lerdelimumab Metelimumab Kinase inhibitors: A 83-01 D-4476 GW-788388 LY-364947 LY-2109761...
7 KB (595 words) - 13:39, 10 September 2024